|
||||||
Executive Summary Curis, Inc.-Product Pipeline Review-2015 Summary Global Markets Direct's, 'Curis, Inc.-Product Pipeline Review-2015', provides an overview of the Curis, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Curis, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides brief overview of Curis, Inc. including business description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Curis, Inc.'s human therapeutic division and enlists all their major and minor projects The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones Special feature on out-licensed and partnered product portfolio The report summarizes all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Curis, Inc.'s pipeline products Reasons To Buy Evaluate Curis, Inc.'s strategic position with total access to detailed information on its product pipeline Assess the growth potential of Curis, Inc. in its therapy areas of focus Identify new drug targets and therapeutic classes in the Curis, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps Develop strategic initiatives by understanding the focus areas of Curis, Inc. and exploit collaboration and partnership opportunities Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Plan mergers and acquisitions effectively by identifying the most promising pipeline of Curis, Inc. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Explore the dormant and discontinued projects of Curis, Inc. and identify potential opportunities in those areas Avoid Intellectual Property Rights related issues Read More Contact Us:
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Curis, Inc. Snapshot 5 Curis, Inc. Overview 5 Key Information 5 Key Facts 5 Curis, Inc.-Research and Development Overview 6 Key Therapeutic Areas 6 Curis, Inc.-Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products-Monotherapy 9 Pipeline Products-Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Curis, Inc.-Pipeline Products Glance 12 Curis, Inc.-Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Curis, Inc.-Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Curis, Inc.-Drug Profiles 14 CUDC-101 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CUDC-427 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CUDC-907 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CUDC-906 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CUDC-908 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Curis, Inc.-Pipeline Analysis 21 Curis, Inc.-Pipeline Products by Target 21 Curis, Inc.-Pipeline Products by Route of Administration 22 Curis, Inc.-Pipeline Products by Molecule Type 23 Curis, Inc.-Pipeline Products by Mechanism of Action 24 Curis, Inc.-Recent Pipeline Updates 25 Curis, Inc.-Dormant Projects 31 Curis, Inc.-Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 CUDC-305 32 Curis, Inc.-Company Statement 33 Curis, Inc.-Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38 List of Tables Curis, Inc., Key Information 5 Curis, Inc., Key Facts 5 Curis, Inc.-Pipeline by Indication, 2015 7 Curis, Inc.-Pipeline by Stage of Development, 2015 8 Curis, Inc.-Monotherapy Products in Pipeline, 2015 9 Curis, Inc.-Partnered Products in Pipeline, 2015 10 Curis, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 11 Curis, Inc.-Phase I, 2015 12 Curis, Inc.-Preclinical, 2015 13 Curis, Inc.-Pipeline by Target, 2015 21 Curis, Inc.-Pipeline by Route of Administration, 2015 22 Curis, Inc.-Pipeline by Molecule Type, 2015 23 Curis, Inc.-Pipeline Products by Mechanism of Action, 2015 24 Curis, Inc.-Recent Pipeline Updates, 2015 25 Curis, Inc.-Dormant Developmental Projects,2015 31 Curis, Inc.-Discontinued Pipeline Products, 2015 32 Curis, Inc., Subsidiaries 36 List of Figures Curis, Inc.-Pipeline by Top 10 Indication, 2015 6 Curis, Inc.-Pipeline by Stage of Development, 2015 8 Curis, Inc.-Monotherapy Products in Pipeline, 2015 9 Curis, Inc.-Partnered Products in Pipeline, 2015 10 Curis, Inc.-Pipeline by Top 10 Target, 2015 21 Curis, Inc.-Pipeline by Top 10 Route of Administration, 2015 22 Curis, Inc.-Pipeline by Top 10 Molecule Type, 2015 23 Curis, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 24 Single User License: Site License: Corporate User License: Current R&D Portfolio of Curis, Inc.; Curis, Inc. - Key Therapeutics; Curis, Inc. - Pipeline Overview and Promising Molecules; Curis, Inc. - News; Curis, Inc. - Latest Updates; Curis, Inc. - Pipeline; Curis, Inc. - Discontinued/Dormant Projects |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center" |